

MEDIA RELEASE

April 06, 2023

medmix Drug Delivery (Haselmeier) and DCA Design International receive Red Dot Award for PiccoJect™ in the product design category

Page 1 of 4

medmix AG
Neuhofstrasse 20
CH-6340 Baar

communications@medmix.com
www.medmix.swiss

MEDIA RELEASE

April 06, 2023

medmix Drug Delivery (Haselmeier) and DCA Design International receive Red Dot Award for PiccoJect™ in the product design category

PiccoJect, the disposable, two-step autoinjector, designed for subcutaneous injection, has now been recognized for another prestigious design award, the Red Dot Award: Product Design 2023. The award will be presented to Haselmeier and DCA Design at the Red Dot Gala on June 19 in Essen, Germany. This is the second design award that medmix, global leader in high-precision delivery devices, and DCA Design International Limited, one of the world's leading product design consultancies, have received for PiccoJect. By the end of 2022, PiccoJect had already been awarded with the Good Design Award.

"We are honored to receive this prestigious design award, which underlines our commitment to developing patient-centered injection devices that help millions of patients live healthier and more confident lives" said Dominik Vonier, Head of medmix Drug Delivery segment. "Haselmeier and DCA had this vision at the beginning of our collaboration to develop an autoinjector that is easy to use, reliable and with an ergonomic, patient-centered design; a truly next generation autoinjector increased ease of use for patients."

PiccoJect is a highly compact, customizable, and fully featured two-step autoinjector designed for subcutaneous delivery of pharmaceuticals and biologics. With a commitment to sustainability, PiccoJect is composed of only eight parts reducing manufacturing and scale up challenges. Confidence that the dose has been delivered is critical for the patient and PiccoJect makes inspection of the syringe and monitoring of the injection progress easy from a wide range of viewing angles. It features a large wrap-around drug window and a status indicator that changes color at the end of the dose, providing clear binary feedback that the injection is completed. The compact external form of PiccoJect is intended to make it less intimidating for patients, whilst being secure and comfortable to hold, especially for those with impaired dexterity. Autoinjectors aim to automate the process of subcutaneous injection from a pre-filled syringe. They are typically used by patients and

MEDIA RELEASE

April 06, 2023

medmix Drug Delivery (Haselmeier) and DCA Design International receive Red Dot Award for PiccoJect™ in the product design category

Page 2 of 4

non-professional care givers at home to self-inject medicines for many chronic and acute illnesses.

PiccoJect is fully customizable based on customer needs including support for different fill volumes and drug viscosities, color options for the cap and an adjustable size of the drug window. In addition, the design of PiccoJect includes several connectivity options that are either integrated or provided as an add-on module, without modifying the core mechanism or compromising handling. Haselmeier is offering PiccoJect as a full-service platform including combination product development, design verification, final assembly, secondary packaging, labeling and serialization.

Red Dot Design Award:

With around 20,000 entries per year, the Red Dot Design Award is one of the biggest design competitions in the world. In order to reach a professional verdict given the diversity of the design sector, the competition is divided into three disciplines: Product Design, Brands & Communication Design and Design Concept. The Red Dot Design Award can look back on a more than 60-year history: 1955 was the first time a jury came together to evaluate the best designs of the time. In the 1990s, Red Dot CEO, Professor Dr Peter Zec, came up with the name and brand for the award. The coveted "Red Dot" award has since become the highly regarded seal for outstanding design quality that is recognized worldwide. Award winners are presented in the yearbooks, museums and online.

Facts and figures about PiccoJect:

- Low part count of only eight components
- Patient-centric design with an ergonomic shape and a large wrap-around drug window
- A full-service platform with consistent and repeatable performance
- Disposable two-step autoinjector for subcutaneous injection
- Developed for a standard 1 ml long or 2.25 ml pre-filled glass or plastic syringes
- Fill volumes from 0.2 ml to 2.0 ml
- Viscosity up to 20 cP

MEDIA RELEASE

April 06, 2023

medmix Drug Delivery (Haselmeier) and DCA Design International receive Red Dot Award for PiccoJect™ in the product design category

Page 3 of 4



PiccoJect received Red Dot Award 2023 and Good Design Award 2022



PiccoJect is easy to customize

MEDIA RELEASE

April 06, 2023

medmix Drug Delivery (Haselmeier) and DCA Design International receive Red Dot Award for PiccoJect™ in the product design category

Page 4 of 4



PiccoJect is easy to use, reliable and has an ergonomic, patient-centric design

About medmix

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2,100 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss

Inquiries:

*Media Relations: Peter Trampert, Senior Communications Manager
communications@medmix.com*

*Investor Relations: Sheel Gill, Head of Investor Relations
investorrelations@medmix.com*

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.